SCHEMBL4553323

SCHEMBL4553323

O=C1C=CC=C2N=NC=C12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13740193 0.98
SCHEMBL30530546 0.74
SCHEMBL11881828 0.70
SCHEMBL7270085 0.69
SCHEMBL1875112 0.69
SCHEMBL3885051 0.68
SCHEMBL3883020 0.68
SCHEMBL3519958 0.68
SCHEMBL27408768 0.67
SCHEMBL28980646 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114867726-A Small molecule inhibitors of KRAS G12C mutant 默沙东公司 2022-08-05 CN claimed
EP-1756087-A1 AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE Wyeth (US) 2007-02-28 EP claimed
WO-2006009653-A1 AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE WYETH (US) 2006-01-26 WO claimed
US-20260035386-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC (US) 2026-02-05 US disclosed
US-20240269230-A1 CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY MEDIZINISCHE UNIVERSITAT WIEN (AT) 2024-08-15 US disclosed
EP-4322954-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2024-02-21 EP disclosed
CN-114867726-B Small molecule inhibitors of KRAS G12C mutants 默沙东有限责任公司 2023-11-28 CN disclosed
WO-2022221739-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT MERCK SHARP & DOHME CORP. (US) 2022-10-20 WO disclosed
CN-114867726-A Small molecule inhibitors of KRAS G12C mutant 默沙东公司 2022-08-05 CN disclosed
US-20220074941-A1 HSP90 COMBINATION THERAPY SLOAN KETTERING INST CANCER RES (US) 2022-03-10 US disclosed
US-20140315929-A1 HSP90 COMBINATION THERAPY SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2014-10-23 US disclosed
WO-2012173849-A1 PYRAZOLE DERIVATIVES USEFUL AS ALDOSTERONE SYNTHASE INHIBITORS ELI LILLY AND COMPANY (US) 2012-12-20 WO disclosed
WO-2012149493-A2 HSP90 COMBINATION THERAPY SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-11-01 WO disclosed
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 EP disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 WO disclosed
EP-1177185-A1 4, 5, 6, 7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS PHARMACIA &amp; UPJOHN S.p.A. (IT) 2002-02-06 EP disclosed
WO-2000069846-A1 4,5,6,7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2000-11-23 WO disclosed
EP-0276834-B1 Cycloalkane [1,2-c:4,3-c'] dipyrazoles MERRELL DOW PHARMACEUTICALS INC. (US) 1993-06-02 EP disclosed
EP-0276834-A1 Cycloalkane [1,2-c:4,3-c'] dipyrazoles MERRELL DOW PHARMACEUTICALS INC. (US) 1988-08-03 EP disclosed
US-4734429-A Cycloalkane[1,2-c:4,3-c']dipyrazoles and their use as bronchodilators MERRELL DOW PHARMACEUTICALS INC. (US) 1988-03-29 US disclosed